– Biospectal raises $ 4.3 million in seed funds led by digital health investor SeedLink
The remote monitoring and patient biosensing company will use the investment to scale its OptiBP ™ blood pressure measurement and monitoring product and operations worldwide; Renowned Interventional Cardiologist and Inventor, Dr. Fred St. Goar , MD, and Tim Juergens , of SeedLink, were appointed to serve on the Board of Directors of Biospectal
LAUSANNE, Switzerland and SAN FRANCISCO , July 21, 2021 / PRNewswire / – Biospectal SA , the biosensors and patient remote monitoring software company, announced today the closing of a $ 4.3 million seed funding round ( € 3.7 million) led by digital health investor SeedLink with additional funding from LabCorp , Athensmed , Privilege Ventures, based in Switzerland, in addition to other European and US investors. Biospectal will take advantage of the new funding to scale its blood pressure monitoring application and its OptiBP ™ smartphone data platform technology worldwide. Biospectal OptiBP for Android was released in public beta in January 2021. Biospectal OptiBP for iOS is currently in alpha version and its public beta release is expected in the second half of 2021. You can watch a short video of how it works Biospectal OptiBP here .
“Biospectal’s technology has the ability to transform the global network of smartphones into a clinically connected blood pressure monitoring platform that moves clinical capabilities beyond traditional institutional settings,” explained Biospectal CEO and Co-Founder. , Eliott Jones . “The funding we have received will accelerate Biospectal’s growth trajectory, in addition to the appointments of Silicon Valley-based serial healthcare innovator and interventional cardiologist, Dr. Fred St. Goar , MD, Tim Juergens., CEO and co-founder of SeedLink, William Hanlon of LabCorp and Kustaa Piha, successful entrepreneur and health technology investor of Athensmed on the board of directors of Biospectal, “added Reinhard Stary , executive chairman of the board of directors.
How Biospectal OptiBP works
Biospectal’s OptiBP medical grade app uses the optical lens of a smartphone camera to easily measure and record a user’s blood pressure flow with a fingertip. Biospectal’s proprietary algorithms and optical signal capture methods are used to transform captured data into blood pressure values in about 20 seconds – half the time required for a typical blood pressure cuff. With Biospectal OptiBP, anyone in the world with a smartphone can turn their device into a clinically-grade, smart, connected monitor with just the time it takes to download and install an app. OptiBP data also seamlessly connects with physicians to support treatment regimens that help improve health and quality of life. Biospectal’s proprietary OptiBP technology replaces the old-fashioned and impractical traditional blood pressure cuff, as well as providing medical-grade blood pressure measurement to the ‘patient point’ without the need for other additional portable device or bulky hardware that can break or needs to be replaced.
According to the CDC, hypertension affects about 46% (100 million) of adults in the United States , and the World Health Organization estimates that there are 1.13 billion people worldwide who have this disease. Called “the silent killer”, only 1 in 5 people affected by hypertension has it under control.
“It is an honor to be able to join Biospectal’s board of directors. Addressing the global hypertension crisis through more frequent and meaningful monitoring has become more critical and important than ever – a necessity than the emergence of COVID- 19 and the demand for telehealth solutions has only amplified. People need an easy-to-use digital medium to accurately measure, control, track and share their blood pressure data with their doctors. Biospectal is the first company I have found in the remote patient monitoring industry to provide accessible, secure and customer access to market-focused blood pressure monitoring technology on a global scale, “said Dr. Fred St. Goar, MD. “Biospectal OptiBP is a game changer that promises to have a major impact on improving access and treating hypertension management.”
Founded in 2017 and supported by grants from the Bill & Melinda Gates Foundation , Grand Challenges Canada and Innosuisse , Biospectal’s proprietary technology has been developed and validated in association with the Swiss Center for Electronics and Microtechnology (CSEM) and represents more than 10 years of non-invasive experience in the R&D sector dedicated to optical biosensing. A recent large-scale third-party clinical research study published by Scientific Reports in Nature validated the OptiBP app’s ability to measure blood pressure with the same precision as a standard cuff. Additionally, in May 2021, Biospectal announced two independent global research and validation studies funded by the Bill & Melinda Gates Foundation and Global Grand Challenges Canada’s Saving Lives at Birth initiative. These studies reinforce Biospectal’s ability to transform the global network of smartphones into a connected, clinical-grade blood pressure monitoring platform – democratizing access and bringing the power of remote patient monitoring to individuals and communities around the world.
“Biospectal OptiBP is an innovative technology that enables more accessible, effective and efficient patient monitoring so that patients can contribute and participate in the clinical regimen for the control and management of chronic diseases,” explained Tim Juergens , CEO and co-founder of SeedLink . “The dynamic of the ‘participatory patient’ is accelerating and forms an integral component within the clinical and research landscape. Biospectal responds to the growing demand for telehealth solutions and will help improve the health and quality of life of millions, and is so we are excited to support the future success of Biospectal. “
About Biospectal
Biospectal SA is the biosensors and remote control software company focused on the global democratization of clinical monitoring. We make it easy for hypertension patients and health-conscious consumers to tackle hypertension, the ‘silent killer’ and the number one chronic health condition globally. Biospectal’s OptiBP ™ smartphone app and data platform removes the traditional barrier of the blood pressure cuff and enables frequent and intelligent monitoring of blood pressure using a fingertip applied to the camera lens. a smart phone. By optically measuring blood flow through the skin, our proprietary algorithm converts light information into blood pressure values. Currently,
Founded in July 2017, Biospectal is based in Lausanne, Switzerland, with an additional office in Silicon Valley. Biospectal’s patented and clinically validated technology was developed in collaboration with the Swiss Center for Electronics and Microtechnology and represents more than 10 years of non-invasive optical biosensing R&D. Read our news , “like” us on Facebook , follow us on Twitter or get more information at https://biospectal.com .
About SeedLink
SeedLink SL helps founders successfully create and develop solutions in the digital health space, with a special emphasis on digital therapeutics (DtX), digital biomarkers, and platform-based business models. SeedLink participates in the pre-seed and seed phases by providing funding, services, and hands-on support, and provides the expertise and the network to unite more than 20 years of experience in healthcare technology, IT, shared services implementation, and leveraging a network of multidisciplinary advisers.
All trademarks used are the property of their respective owners.
Related Links
SOURCE Biospectal
